

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from scanned originals with text recognition applied
(searchable text may contain some errors and/or omissions)

m
RCS

L.D. 1618

DATE: 6/9/15

(Filing No. H-675)

Reproduced and distributed under the direction of the Clerk of the House.

STATE OF MAINE
HOUSE OF REPRESENTATIVES
122ND LEGISLATURE
FIRST SPECIAL SESSION

HOUSE AMENDMENT "A" to COMMITTEE AMENDMENT "A" to H.P. 1141, L.D. 1618, Bill, "An Act Regarding Advertising by Drug Manufacturers"

Amend the amendment by inserting after the title the following:

'Amend the bill by striking out the title and substituting the following:

'An Act Regarding Advertising by Drug Manufacturers and Disclosure of Clinical Trials'

Further amend the amendment in the first paragraph after the title in the first line (page 1, line 22 in amendment) by striking out the following: "Amend" and inserting in its place the following: 'Further amend'

Further amend the amendment in section 1 in that part designated "~~§2700-A.~~" in subsection 3 by striking out all of the first indented paragraph (page 2, lines 27 to 36 in amendment) and inserting in its place the following:

'3. Disclosure of clinical trials of prescription drugs. Beginning October 15, 2005, a manufacturer or labeler of prescription drugs that is required to report marketing costs for prescription drugs pursuant to section 2698-A shall post, with regard to those prescription drugs, on the publicly accessible Internet website of the federal National Institutes of Health or its successor agency or another publicly accessible website the following information concerning any clinical trial that the manufacturer conducted or sponsored on or after October 15, 2002:'

B. 118

HOUSE AMENDMENT "A" to COMMITTEE AMENDMENT "A" to H.P. 1141,
L.D. 1618

2

SUMMARY

4 This amendment removes the provision that requires a
6 manufacturer of prescription drugs to disclose certain
8 information regarding clinical trials of prescription drugs
10 before regulated advertisements for those prescription drugs may
12 be presented and replaces it with a requirement that a
14 manufacturer or labeler of prescription drugs that is required to
16 report marketing costs for prescription drugs pursuant to the
18 Maine Revised Statutes, Title 22, section 2698-A disclose certain
20 information regarding clinical trials of prescription drugs.

14

16

18

SPONSORED BY:
(Representative LERMAN)

20

22

TOWN: Augusta

24